David B. Agus
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
David B. Agus has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
Anna V. Galkin
Louis Warschaw Prostate Cancer Center, Cedars‐Sinai Medical Center and
3 shared publicationsAnjali Jain
Louis Warschaw Prostate Cancer Center, Cedars‐Sinai Medical Center and
2 shared publicationsStuart Holden
Louis Warschaw Prostate Cancer Center, Cedars‐Sinai Medical Center and
2 shared publicationsBrian Higgins
1 shared publication- Carlos Cordon-Cardo
Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
1 shared publication David Duncan
Department of Molecular Biology, Corvas International, San Diego, California
1 shared publication
Latest Publications
- 20 December 2005
- Published by Wiley in BJU International
- Vol. 97 (4) , 691-697
Raloxifene, an oestrogen‐receptor‐β‐targeted therapy, inhibits androgen‐independent prostate cancer growth: results from preclinical studies and a pilot phase II clinical trial
OBJECTIVES: To determine, in preclinical in vivo animal and in clinical studies, whether raloxifene (a selective oestrogen‐receptor (ER) modulator that targets ER‐β and induces apoptosis in vitro in androgen‐independent prostate cancer, AIPC cells) affects prostate cell differentiation, proliferation and carcinogenesis, and in the pilot phase II clinical trial, the response rate and duration of patients with AIPC treated with a daily oral dose of raloxifene. PATIENTS, MATERIALS AND METHODS: Tumour proliferation rate in response to raloxifene treatment, and molecular markers of cell cycle and apoptosis, were evaluated in established ER‐β‐positive androgen‐dependent (AD) CWR22 and AI CWRSA9 human xenograft prostate cancer models. Twenty‐one patients with AIPC and evidence of disease progression were enrolled into the clinical trial and given daily oral raloxifene. RESULTS: There was significant growth inhibition by raloxifene in the ADPC and AIPC xenograft models (CWR22 68%, P < 0.010; CWRSA9 64%, P < 0.001), with no tumour regression. There was evidence of G1 arrest by increased p27kip1 expression in the raloxifene‐treated group. Eighteen patients comprised the efficacy analysis, as three withdrew before the first evaluation. At the first evaluation, five men had stable disease and continued on the study for a median of five cycles. The longest response was 17 cycles. Drug related toxicity was minimal. CONCLUSION: Raloxifene has activity in xenograft models, slowing disease progression. This translated to possible disease stabilization in patients with AIPC. Further studies are warranted.
- 20 December 2005
- Published by Wiley in BJU International
- Vol. 97 (4) , 691-697
Raloxifene, an oestrogen‐receptor‐β‐targeted therapy, inhibits androgen‐independent prostate cancer growth: results from preclinical studies and a pilot phase II clinical trial
OBJECTIVES: To determine, in preclinical in vivo animal and in clinical studies, whether raloxifene (a selective oestrogen‐receptor (ER) modulator that targets ER‐β and induces apoptosis in vitro in androgen‐independent prostate cancer, AIPC cells) affects prostate cell differentiation, proliferation and carcinogenesis, and in the pilot phase II clinical trial, the response rate and duration of patients with AIPC treated with a daily oral dose of raloxifene. PATIENTS, MATERIALS AND METHODS: Tumour proliferation rate in response to raloxifene treatment, and molecular markers of cell cycle and apoptosis, were evaluated in established ER‐β‐positive androgen‐dependent (AD) CWR22 and AI CWRSA9 human xenograft prostate cancer models. Twenty‐one patients with AIPC and evidence of disease progression were enrolled into the clinical trial and given daily oral raloxifene. RESULTS: There was significant growth inhibition by raloxifene in the ADPC and AIPC xenograft models (CWR22 68%, P < 0.010; CWRSA9 64%, P < 0.001), with no tumour regression. There was evidence of G1 arrest by increased p27kip1 expression in the raloxifene‐treated group. Eighteen patients comprised the efficacy analysis, as three withdrew before the first evaluation. At the first evaluation, five men had stable disease and continued on the study for a median of five cycles. The longest response was 17 cycles. Drug related toxicity was minimal. CONCLUSION: Raloxifene has activity in xenograft models, slowing disease progression. This translated to possible disease stabilization in patients with AIPC. Further studies are warranted.
- Open Access
- 1 June 2004
- Published by Elsevier in Cancer Cell
- Vol. 5 (6) , 565-574
Inhibition of HER-kinase activation prevents ERK-mediated degradation of PPARγ
- 1 June 2004
- Published by Elsevier in Cancer Cell
- Vol. 5 (6) , 565-574
Open AccessInhibition of HER-kinase activation prevents ERK-mediated degradation of PPARγ
- 15 April 2004
- Published by Wiley in The Prostate
- Vol. 61 (3) , 228-235
CVS‐3983, a selective matriptase inhibitor, suppresses the growth of androgen independent prostate tumor xenografts
BACKGROUND: Matriptase, a type‐II transmembrane serine protease, is expressed by cancers of epithelial origin including breast, colon, and prostate carcinomas and has been implicated in tumor growth and progression. We studied the effects of CVS‐3983, a selective small molecule matriptase inhibitor, on the growth of the androgen independent (AI) CWR22R and CWRSA6 human prostate cancer xenograft models.METHODS: CVS‐3983 was administered i.p. twice‐daily 7‐days per week for 2–3 weeks to mice with established tumors. Measurements of tumor volume were made twice weekly. The effect of CVS‐3983 on CWR22RV1 cell invasion through a reconstituted basement membrane matrix of proteins was also evaluated. Matriptase expression across the tumor lines was assessed by RT‐PCR and Western blotting.RESULTS: CVS‐3983 inhibited final mean tumor volume by 65.5% (n = 10, P = 0.0002) in the CWR22R model and by 56.2% (n = 8, P = 0.0017) in the CWRSA6 tumor model compared with vehicle‐treated tumors. CVS‐3983 did not inhibit the proliferation of CWR22RV1 cells in vitro; however, the small molecule did significantly reduce by 30.2% the invasion of these cells in vitro through a reconstituted basement membrane matrix. Molecular analysis of the xenograft tumors demonstrated high expression levels of matriptase at the RNA and protein levels, which were not affected by CVS‐3983 treatment.CONCLUSIONS: These results identify CVS‐3983 as a potent inhibitor of AI prostate cancer cell invasion in vitro and established xenograft tumor growth in vivo.
- 15 April 2004
- Published by Wiley in The Prostate
- Vol. 61 (3) , 228-235
CVS‐3983, a selective matriptase inhibitor, suppresses the growth of androgen independent prostate tumor xenografts
BACKGROUND: Matriptase, a type‐II transmembrane serine protease, is expressed by cancers of epithelial origin including breast, colon, and prostate carcinomas and has been implicated in tumor growth and progression. We studied the effects of CVS‐3983, a selective small molecule matriptase inhibitor, on the growth of the androgen independent (AI) CWR22R and CWRSA6 human prostate cancer xenograft models.METHODS: CVS‐3983 was administered i.p. twice‐daily 7‐days per week for 2–3 weeks to mice with established tumors. Measurements of tumor volume were made twice weekly. The effect of CVS‐3983 on CWR22RV1 cell invasion through a reconstituted basement membrane matrix of proteins was also evaluated. Matriptase expression across the tumor lines was assessed by RT‐PCR and Western blotting.RESULTS: CVS‐3983 inhibited final mean tumor volume by 65.5% (n = 10, P = 0.0002) in the CWR22R model and by 56.2% (n = 8, P = 0.0017) in the CWRSA6 tumor model compared with vehicle‐treated tumors. CVS‐3983 did not inhibit the proliferation of CWR22RV1 cells in vitro; however, the small molecule did significantly reduce by 30.2% the invasion of these cells in vitro through a reconstituted basement membrane matrix. Molecular analysis of the xenograft tumors demonstrated high expression levels of matriptase at the RNA and protein levels, which were not affected by CVS‐3983 treatment.CONCLUSIONS: These results identify CVS‐3983 as a potent inhibitor of AI prostate cancer cell invasion in vitro and established xenograft tumor growth in vivo.
- 1 October 2002
- Vol. 8 (10) , 3226-31
Antibody to vascular endothelial growth factor slows growth of an androgen-independent xenograft model of prostate cancer.
Human tumors are dependent on angiogenesis for growth, and vascular endothelial growth factor (VEGF) is a major regulator of this process. We aimed to study clinical utility of a recombinant humanized monoclonal anti-VEGF antibody (rhu alpha VEGF) in the treatment of the CWR22R androgen-independent xenograft model of prostate cancer. rhu alpha VEGF has previously shown clinical activity in several xenograft cancer models. We administered 5 mg/kg rhu alpha VEGF i.p. twice weekly as a single agent and together with paclitaxel to established CWR22R xenografts. rhu alphaVEGF inhibited established tumor growth by 85% (P < 0.01 for trajectories of the average tumor volumes of the groups) at 3 weeks, but after cessation of rhu alpha VEGF treatment, tumor regrowth ensued. A paclitaxel dosage of 6.25 mg/kg s.c. five times/week slowed tumor growth (72% compared with controls at 3 weeks, P = 0.02). The combination of paclitaxel and rhu alpha VEGF resulted in greater inhibition of tumor growth than that observed with either agent alone (98% growth inhibition, P = 0.024 versus rhualpha VEGF alone and P = 0.02 versus paclitaxel alone). Paclitaxel alone had no antiangiogenic effects at the dosage studied, whereas rhu alpha VEGF had significant inhibition of angiogenesis, noted by microvessel density and CD34 staining. rhu alpha VEGF has cytostatic clinical activity in this androgen-independent prostate cancer xenograft model, and the addition of paclitaxel demonstrates increased clinical activity.
- 1 October 2002
- Vol. 8 (10) , 3226-31
Antibody to vascular endothelial growth factor slows growth of an androgen-independent xenograft model of prostate cancer.
Human tumors are dependent on angiogenesis for growth, and vascular endothelial growth factor (VEGF) is a major regulator of this process. We aimed to study clinical utility of a recombinant humanized monoclonal anti-VEGF antibody (rhu alpha VEGF) in the treatment of the CWR22R androgen-independent xenograft model of prostate cancer. rhu alpha VEGF has previously shown clinical activity in several xenograft cancer models. We administered 5 mg/kg rhu alpha VEGF i.p. twice weekly as a single agent and together with paclitaxel to established CWR22R xenografts. rhu alphaVEGF inhibited established tumor growth by 85% (P < 0.01 for trajectories of the average tumor volumes of the groups) at 3 weeks, but after cessation of rhu alpha VEGF treatment, tumor regrowth ensued. A paclitaxel dosage of 6.25 mg/kg s.c. five times/week slowed tumor growth (72% compared with controls at 3 weeks, P = 0.02). The combination of paclitaxel and rhu alpha VEGF resulted in greater inhibition of tumor growth than that observed with either agent alone (98% growth inhibition, P = 0.024 versus rhualpha VEGF alone and P = 0.02 versus paclitaxel alone). Paclitaxel alone had no antiangiogenic effects at the dosage studied, whereas rhu alpha VEGF had significant inhibition of angiogenesis, noted by microvessel density and CD34 staining. rhu alpha VEGF has cytostatic clinical activity in this androgen-independent prostate cancer xenograft model, and the addition of paclitaxel demonstrates increased clinical activity.
- 1 January 2000
- Published by Taylor & Francis in Cancer Investigation
- Vol. 18 (5) , 501-502
Book Review
- 1 January 2000
- Published by Taylor & Francis in Cancer Investigation
- Vol. 18 (5) , 501-502
Book Review